Lilly Tries to Buy Time
Executive Summary
Facing a steep patent cliff and a dearth of late-stage drugs, Lilly is slashing expenses, reorganizing R&D, and hoping to attract investors to share the risks and rewards of pipeline development. Will these moves be enough?
You may also be interested in...
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Unbowed by a string of recent pipeline setbacks, Lilly Research Labs' new leader speaks out about his company's current trajectory and his belief in ongoing initiatives like Chorus and a mirror fund as Lilly attempts to bridge its patent cliff.
Inside Lilly Research Laboratories: A Discussion With Jan Lundberg
Unbowed by a string of recent pipeline setbacks, Lilly Research Labs' new leader speaks out about his company's current trajectory and his belief in ongoing initiatives like Chorus and a mirror fund as Lilly attempts to bridge its patent cliff.
Lilly Closes Its Singapore Drug Discovery Center; Is China Discovery Unit In The Works?
Eli Lilly announced Oct. 18 that it will shut the doors of its eight-year-old Lilly Singapore Center for Drug Discovery